Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Apoptosis-based therapies for hematologic malignancies.

John C Reed1, Maurizio Pellecchia

  • 1Burnham Institute, 10901 N Torrey Pines Rd, La Jolla, CA 92037, USA. reedoffice@burnham.org

Blood
|March 31, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

K63 ubiquitination in immune signaling.

Trends in immunology·2022
Same author

Correction: Regulation of ATG4B Stability by RNF5 Limits Basal Levels of Autophagy and Influences Susceptibility to Bacterial Infection.

PLoS genetics·2020
Same author

Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.

Frontiers in immunology·2019
Same author

Human DPP9 represses NLRP1 inflammasome and protects against autoinflammatory diseases via both peptidase activity and FIIND domain binding.

The Journal of biological chemistry·2018
Same author

Oxidized analogs of Di(1<i>H</i>-indol-3-yl)methyl-4-substituted benzenes are NR4A1-dependent UPR inducers with potent and safe anti-cancer activity.

Oncotarget·2018
Same author

Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer.

Cancer discovery·2018
Same journal

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same journal

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same journal

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Blood·2026
Same journal

Decentralized Clinical Trials in Hematology: the Promise and the Peril.

Blood·2026
Same journal

How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

Blood·2026
Same journal

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026
See all related articles

Apoptosis, or programmed cell death, is vital for maintaining tissue balance. Understanding its mechanisms offers new therapeutic targets for leukemia and lymphoma.

Area of Science:

  • Cell Biology
  • Immunology
  • Oncology

Background:

  • Apoptosis is a crucial cell death program for tissue homeostasis, particularly in rapidly self-renewing tissues like the hematopoietic system.
  • Key discoveries in apoptosis include glucocorticoid-induced thymocyte apoptosis (1980) and factor-dependent hematopoietic cell death (1990).

Purpose of the Study:

  • To review drug discovery targets within the core apoptosis machinery.
  • To describe progress in developing new therapies for leukemia and lymphoma based on apoptosis research.

Main Methods:

  • Literature review of apoptosis mechanisms in lymphoid and hematopoietic cells.
  • Identification and discussion of drug discovery targets within the apoptotic pathway.

Main Results:

Related Experiment Videos

  • Significant progress has been made in understanding the molecular and structural components of apoptosis.
  • Several potential therapeutic targets have been identified within the core apoptotic machinery.

Conclusions:

  • Understanding apoptosis provides a foundation for novel therapeutic strategies against hematological malignancies.
  • Targeting apoptosis holds promise for developing new treatments for leukemia and lymphoma.